AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Choline kinase alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P35790

UPID:

CHKA_HUMAN

Alternative names:

CHETK-alpha; Ethanolamine kinase

Alternative UPACC:

P35790; Q8NE29

Background:

Choline kinase alpha (CHKA), also known as CHETK-alpha and Ethanolamine kinase, is pivotal in phospholipid biosynthesis. It catalyzes the phosphorylation of choline to phosphocholine, a critical step in phosphatidylcholine production. CHKA also contributes to phosphatidylethanolamine biosynthesis by phosphorylating ethanolamine. Its activity is notably higher with choline. Furthermore, CHKA plays a significant role in lipolysis of lipid droplets under glucose deprivation, indicating its involvement in cellular energy management.

Therapeutic significance:

CHKA is linked to a neurodevelopmental disorder characterized by severe developmental delay, microcephaly, and seizures. This association underscores its potential as a target for therapeutic intervention in genetic disorders affecting neurodevelopment. Understanding the role of Choline kinase alpha could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.